Thromb Haemost 2010; 104(05): 863-866
Schattauer GmbH
Oscar D. Ratnoff: A man for all seasons
Alvin H. Schmaier
1
Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, USA
› Author Affiliations
References
1
Saito H.
Studies on Fletcher trait and Fitzgerald trait.. Thromb Haemost 2010; 104: 867-874.
2
Hathaway WE,
Belhasen LP,
Hathaway HS.
Evidence for a new plasma thromboplastin factor. 1. Case report, coagulations studies, and physiological properties.. Blood 1965; 26: 521-532.
3
Saito H,
Ratnoff OD,
Donaldson VH.
et al.
Fletcher factor deficiency.. Blood 1972; 39: 745-747.
4
Waldmann R,
Abraham JP,
Rebuck JW.
et al.
Fitzgerald factor: a hitherto unrecognized coagulation factor.. Lancet 1975; 01: 949-952.
5
Saito H,
Ratnoff OD,
Waldmann R.
et al.
Fitzgerald trait: Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis and generation of kinins and PE/Dil.. J Clin Invest 1975; 55: 1082-1089.
6
Krijanovski Y,
Proulle V,
Mahdi F.
et al.
Characterization of molecular defects of Fitzgerald trait and another novel high molecular weight kininogen deficient patient: Insights into structural requirements for kininogen expression.. Blood 2003; 101: 4430-4436.
7
Colman RW,
Bagdassarian A,
Talamo RC.
et al.
Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.. J Clin Invest 1975; 56: 1650-1662.
8
Cheung PP,
Kinapuli SP,
Scott CF.
et al.
Genetic basis of total kininogen deficiency in Williams’ trait.. J Biol Chem 1993; 268: 23361-23365.
9
Colman RW,
Wu Y,
Liu Y.
Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signaling.. Thromb Haemost 2010; 104: 875-885.
10
Colman RW,
Najamunnisa PR,
Yan W.
et al.
Binding of high molecular weight kininogen to human endothelial cells is mediated via a sight within domains 2 and 3 of the urokinase receptor.. J Clin Invest 1997; 100: 1481-1487.
11
LaRusch GA,
Mahdi F,
Shariat-Madar Z.
et al.
Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis.. Blood 2010; 115: 5111-5120.
12
Schmaier AH,
LaRusch G.
Factor XII: New life for an old protein.. Thromb Haemost 2010; 104: 915-918.
13
Mahdi F,
Shariat-Madar Z,
Kuo A.
et al.
Mapping the interaction between high molecular weight kininogen and the urokinase plasminogen activator receptor.. J Biol Chem 2004; 279: 16621-16628.
14
Schmeidler-Sapiro KT,
Ratnoff OD,
Gordon EM.
Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.. Proc Natl Acad Sci USA 1991; 88: 4382-4385.
15
Renne T,
Pozgajova M,
Gruner S.
et al.
Defective thrombus formation in mice lacking coagulation factor XII.. J Exp Med 2005; 202: 271-281.
16
Merkoulov S,
Komar AA,
Schmaier AH.
et al.
Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.. Blood 2008; 111: 1274-1281.
17
van der Meijden PEJ,
Munnix IC,
Auger JM.
et al.
Dual role of collagen in factor XII-dependent thrombus formation.. Blood 2009; 114: 881-890.
18
Wilner GD,
Nossel HL,
LeRoy EC.
Activation of Hageman factor by collagen.. J Clin Invest 1968; 47: 2608-2615.
19
Ratnoff OD.
Activation of Hageman factor by L-homocystine.. Science 1968; 162: 1007-1009.
20
Greip MA,
Fujikawa K,
Nelsestuen GL.
Possible basis for the apparent surface selectivity of the contact activation of human blood coagulation factor XII.. Biochemistry 1986; 25: 6688-6694.
21
Brower MS,
Harpel PC.
Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.. J Biol Chem 1982; 257: 9849-9854.
22
Stief TW,
Heimburger N.
Inactivation of serine proteinase inhibitors (serpins) in human plasma by reactive oxidants.. Biol Chem Hoppe Seyler 1988; 369: 1337-1342.
23
Chang NS,
Boackle RJ,
Leu RW.
Characterization of C1 inhibitor binding to neutrophils.. Immunology 1991; 73: 95-101.
24
Davis AE III,
Lu F,
Mejia P.
C1 inhibitor, a multi-functional serine protease inhibitor.. Thromb Haemost 2010; 104: 886-893.
25
Ruggeri ZM,
Zimmerman TS.
Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/ von Willebrand factor in plasma and platelets.. J Clin Invest 1980; 65: 1318-1325.
26
Ruggeri Z,
Zarpellon A,
Roberts JR.
et al.
Unraveling mechanism and significance of thrombin binding to platelet glycoprotein 1b.. Thromb Haemost 2010; 104: 894-902.
27
Poon M-C,
Rand MI,
Jackson SC.
2B or not to be – the 45-year saga of the Montreal Platelet syndrome.. Thromb Haemost 2010; 104: 903-910.
28
Milton JG,
Frojmovic MM,
Tang SS.
et al.
Spontaneous platelet aggregation in Hereditary Giant Platelet syndrome (MPS).. Am J Path 1984; 114: 336-335.
29
Ruggeri ZM,
Pareti FI,
Mannucci PM.
et al.
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease.. New Engl J Med 1980; 302: 1047-1051.
30
Lederman MM.
Haemophilia, human immuno-deficiency virus and human immunodeficiency virus pathgenesis.. Thromb Haemost 2010; 104: 911-914.
31
Lederman MM,
Ratnoff OD,
Scillian JJ.
et al.
Impaired cell-mediated immunity in patients with classic haemophilia.. N Engl J Med 1983; 308: 79-83.
